Kyle Potts

Employment

• University of Calgary Research Associate
  2021 - Present

Education

• University of Alberta PhD
  2011 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• A B1a–natural IgG–neutrophil axis is impaired in viral- and steroid-associated aspergillosis
  Science Translational Medicine 2022 DOI: 10.1126/scitranslmed.abq6682
  +Save
• Stroke-associated intergenic variants modulate a human FOXF2 transcriptional enhancer
  Proceedings of the National Academy of Sciences 2022 DOI: 10.1073/pnas.2121333119
  +Save
• Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
  Molecular therapy : the journal of the American Society of Gene Therapy 2022 DOI: 10.1016/j.ymthe.2022.04.025
  +Save
• Novel colchicine derivative CR42-24 demonstrates potent anti-tumor activity in urothelial carcinoma.
  Cancer letters 2021 DOI: 10.1016/j.canlet.2021.11.028
  +Save
• Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.
  Molecular therapy : the journal of the American Society of Gene Therapy 2021 DOI: 10.1016/j.ymthe.2021.10.008
  +Save
• Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro
  International Journal of Molecular Sciences 2021 DOI: 10.3390/ijms22094699
  +Save
• Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.
  EMBO molecular medicine 2017 DOI: 10.15252/emmm.201607296
  +Save
• Endothelial calcium-activated potassium channels as therapeutic targets to enhance availability of nitric oxide
  Canadian Journal of Physiology and Pharmacology 2012 DOI: 10.1139/Y2012-075
  +Save
• Oncolytic viruses in the treatment of bladder cancer
  Advances in Urology 2012 DOI: 10.1155/2012/404581
  +Save